Source:Journal of Allergy and Clinical Immunology
Author(s): Michael R. Goldberg, Arnon Elizur, Liat Nachshon, Michael Y. Appel, Michael B. Levy, Keren Golobov, Robert Goldberg, Miguel Stein, Marc E. Rothenberg, Yitzhak Katz
Teaser
Capsule Summary: Oral immunotherapy-induced gastrointestinal and eosinophilic responses (OITIGER) is an adverse response to OIT in ∼8% of patients and is typically reversible by decreasing dosage administration. The peripheral blood eosinophil count serves as a biomarker marker for susceptibility and the medical course.http://ift.tt/2gxKOrh
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου